This is a multicenter, open-label phase I/II study for participants with advanced solid tumors who have failed prior immune checkpoint inhibitor therapies.
Fully understand the study and voluntarily sign the informed consent form.
Male or female 18-75 years of age.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
PART 1: Histologically confirmed unresectable locally advanced, recurrent, or metastatic solid tumors.PART 2 Cohort A: Histologically confirmed unresectable locally advanced, recurrent, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. Cohort B: Histologically confirmed unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma. Cohort C: Histologically confirmed unresectable locally advanced, recurrent, or metastatic other solid tumors.
participants were deemed unsuitable for participating in the study by the investigator for any reasons.
Sequential
ZG005
DrugZG005 20mg/kg; once every 3 weeks；IV infusion
Gecacitinib
DrugGecacitinib for dose escalations are set as 100mg Bid po. Gecacitinib for dose expansion will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
Dose Limiting Toxicity (DLT)
Objective Response Rate (ORR)
Adverse events (AEs)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
